Indrayani Biotech gets ₹13.90 cr tax demand quashed, sent back for fresh look
The ITAT ruling removes an immediate liability equal to 22% of market cap for the nano-cap company, though the matter is remanded.
— 1 earlier story on Indrayani Biotech Ltd. →What's new
- ITAT quashed the First Appellate Authority's order on a ₹13.90 crore tax demand for AY23-24.
- Matter remanded to the First Appellate Authority for fresh adjudication.
- Immediate threat of a cash outflow equal to 22% of market cap is removed.
Why this matters
For a nano-cap with a market cap of just ₹63 crore (at the time of demand) and a stalled ₹50 crore rights issue, a ₹13.90 crore tax liability could have been crippling. The tribunal's intervention buys breathing room, though the final outcome remains uncertain.
What we're watching
- Fresh adjudication timeline and whether the demand is reduced or upheld.
- Any update on the halted rights issue, as the company still needs capital.
The full read
Indrayani Biotech just got a ₹13.90 crore tax demand knocked back by the Income Tax Appellate Tribunal, a sum that at the time equaled 22% of its market cap. The tribunal quashed the earlier appellate order and sent the case for fresh adjudication, removing the immediate threat of a payout that could have crippled a nano-cap already sitting on a stalled ₹50 crore rights issue. The ruling is a clear positive: it changes the risk calculus for a company with ₹76 crore market cap, 1.89x debt-to-equity, and zero net profit in the latest quarter. But fresh adjudication means the tax cloud hasn't lifted, just paused. The real test remains whether Indrayani can get its capital raising back on track.
Questions answered
- What exactly did the ITAT decide?
- The Income Tax Appellate Tribunal quashed the earlier appellate order that had upheld a ₹13.90 crore tax demand against Indrayani Biotech for assessment year 2023-24. It sent the case back to the First Appellate Authority for a fresh hearing.
- How significant is ₹13.90 crore for Indrayani Biotech?
- At the time, the demand was about 22% of the company's ₹63 crore market capitalisation. For a company already struggling with financial distress and a stalled rights issue, that level of liability could have been severe.
- Does this mean the tax dispute is over?
- No. The matter is remanded to the First Appellate Authority for fresh adjudication. The immediate threat of payment is removed, but the ultimate tax liability could still be confirmed or reduced after the next hearing.
- How does this affect the company's liquidity?
- In the near term, it removes a large contingent cash outflow, improving liquidity. However, the company's ₹50 crore rights issue remains stalled, so capital constraints persist.
Indrayani Biotech Ltd.
Latest quarter · Dec 2025
Strength & growth
Story so far
All notes on INDRANIB →- 15 Jul 2026 · 5:18 PM IST Indrayani Biotech gets ₹13.90 cr tax demand quashed, sent back for fresh look
- 23d ago Indrayani Biotech halts ₹50 cr rights issue indefinitely